NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

An Anti-CD45 RO Immunotoxin Eliminates Latently HIV-Infected Cells In Vitro.

MCCOIG C, VANDYKE G, PICKER L, RAMILO O, VITETTA ES; Interscience Conference on Antimicrobial Agents and Chemotherapy.

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 1999 Sep 26-29; 39: 514 (abstract no. 1846).

Univ. of Texas Southwestern Med. Ctr., Dallas, TX.

Despite the success of HAART in controlling plasma viremia in most HIV-infected individuals, several studies have demonstrated the presence of a reservoir of latently infected cells in these individuals. The majority of these cells are CD45 RO+ memory cells. We have previously demonstrated that latently infected cells can be generated in vitro after eliminating CD25+ cells with an immunotoxin (IT) and, following activation, the CD25[-] cells produce HIV. The present study was designed to determine whether these cells could be eliminated by an IT directed against CD45 RO. Peripheral blood mononuclear cells (PBMCs) were infected with HIV, and HIV-producing cells were eliminated with the anti-CD25 IT. The remaining latently infected cells were then treated with an IT directed against CD45 RO, or were cultured in medium (control). After extensive washing, cells were activated with PHA for 3 days to stimulate viral production, and p24 concentrations were measured. PBMCs treated first with the anti-CD25 IT and then with the anti-CD45 RO IT, showed a >90% reduction in p24 production as compared to cells treated with the anti CD25 IT alone. Our results indicate that the anti-CD45 RO IT eliminates in vitro latently HIV-infected cells. Future studies will be required to determine whether the anti CD45 RO IT can also eliminate latently infected cells from HIV-infected individuals.

Publication Types:
  • Meeting Abstracts
Keywords:
  • AIDS Vaccines
  • Acquired Immunodeficiency Syndrome
  • Anti-HIV Agents
  • Antigens, CD45
  • Antiretroviral Therapy, Highly Active
  • HIV
  • HIV Core Protein p24
  • HIV Infections
  • HIV Protease Inhibitors
  • HIV Seropositivity
  • Immunotoxins
  • In Vitro
  • Receptors, Interleukin-2
  • Viremia
  • immunology
Other ID:
  • GWAIDS0008224
UI: 102245721

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov